These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 26123280)

  • 1. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
    Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
    Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
    [No Abstract]   [Full Text] [Related]  

  • 2. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
    Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H
    Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tafamidis for transthyretin amyloidosis.
    de Lartigue J
    Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Merkies IS
    Neurology; 2013 Apr; 80(15):1444-5. PubMed ID: 23569001
    [No Abstract]   [Full Text] [Related]  

  • 5. Poor outcome after liver transplantation for transthyretin amyloid neuropathy in a family with an Ala36Pro transthyretin mutation: case report.
    Muller KR; Padbury R; Jeffrey GP; Poplawski NK; Thompson P; Tonkin A; Harley HA
    Liver Transpl; 2010 Apr; 16(4):470-3. PubMed ID: 20373457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S; Rossello A; Orlandini E
    ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
    Sekijima Y
    Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it better than it seems or just good enough? The tafamidis saga.
    de Carvalho M
    Muscle Nerve; 2012 Dec; 46(6):839-40. PubMed ID: 23042137
    [No Abstract]   [Full Text] [Related]  

  • 10. [Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina].
    Chaves M; Bettini M; Marciano S; Sáez S; Cristiano E; Rugiero M
    Medicina (B Aires); 2016; 76(2):105-8. PubMed ID: 27135849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary transthyretin amyloidosis caused by the rare Phe33Leu mutation.
    Björkenheim A; Szabó B; Sztaniszláv ÁJ
    BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31932463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis.
    Socie P; Benmalek A; Cauquil C; Piekarski E; Kounis I; Eliahou L; Rousseau A; Rouzet F; Echaniz-Laguna A; Samuel D; Adams D; Slama MS; Algalarrondo V
    Amyloid; 2023 Sep; 30(3):303-312. PubMed ID: 36795029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of cardiac transthyretin amyloidosis: an update.
    Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
    Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
    Sekijima Y
    Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A woman with a rare p.Glu74Gly transthyretin mutation presenting exclusively with a rapidly progressive neuropathy: a case report.
    Schänzer A; Kimmich C; Röcken C; Haverkamp T; Weidner I; Acker T; Krämer HH
    J Med Case Rep; 2014 Dec; 8():403. PubMed ID: 25471118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial amyloidotic polyneuropathy and transthyretin.
    Nagasaka T
    Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis.
    Ikeda SI; Hineno A; Ichikawa T; Makino M
    Amyloid; 2019 Jun; 26(2):99-100. PubMed ID: 31090446
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.